The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma

Recruiting Phase 2 Interventional Study
Pleural Mesothelioma Pleural Diseases Cancer FAPI Fibroblast Activation Protein Inhibitor
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Diagnostic
Participants needed
70 (estimated)
Sponsor
Aalborg University Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging. The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT). The diagnostic accuracy will be determined with histopathology as reference standard. For patients undergoing anticancer treatment (…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients with pleural lesions suspicious of pleural mesothelioma and referred to pleural biopsy. * Undergone/undergoing FDG PET/CT as part of the diagnostic workup of a suspicious PM lesion. * Considered physically and mentally able to participate in the research project. * Un…
Contacts

Morten Bentestuen, MD

+45 97665500

m.bentestuen@rn.dk

CONTACT